Host response to influenza is highly variable, suggesting a potential role of host genetic variation. To investigate the host genetics of severe influenza in a targeted fashion, 32 single nucleotide polymorphisms (SNPs) within viral immune response genes were evaluated for association with seasonal influenza hospitalization in an adult study population with European ancestry. SNP allele and genotype frequencies were compared between hospitalized influenza patients (cases) and population controls in a case-control study that included a discovery group (26 cases and 993 controls) and two independent, validation groups (1 with 84 cases and 4076 controls; the other with 128 cases and 9187 controls).
| INTRODUCTION
Human influenza infections are common, and outcomes range from mild or asymptomatic infection to life-threatening illness. Both animal and human studies suggest that host genetic variation is a contributor to influenza infection severity, [1] [2] [3] and several human studies have investigated a potentially functional single nucleotide polymorphism (SNP), rs12252, located at a predicted splice acceptor site in interferon-inducible transmembrane protein 3 (IFITM3), an anti-viral effector that mediates the host innate immune response to influenza infection. [4] [5] [6] [7] The minor CC genotype of rs12252 was associated with hospitalized influenza in patients of European ancestry and with severe influenza in a Han Chinese study population. 3, 8 Further, the CC genotype was associated with severe clinical infection by avian-origin H7N9 influenza virus. 9 However, three other studies were unable to confirm the association between the CC genotype and severe influenza. [10] [11] [12] Knowledge of host genetic variants that are associated with influenza severity could be useful for identifying subpopulations at higher risk for severe influenza infection and might also yield insight into molecular mechanisms that underlie aberrant response to influenza infection. Because the role of host genetics as a modulator of influenza illness severity is understudied and evidence from animal studies suggests that host susceptibility to influenza is not controlled by a single genetic locus, 13 this study sought to evaluate a set of candidate SNPs in genes involved in immune response to viral infection, including IFITM3 rs12252, for association with severe (hospitalized) seasonal influenza. It also attempted to validate the results of hospitalized influenza analyses using independent study samples.
| MATERIALS AND METHODS

| Study subjects
The study included three groups of subjects: a discovery group and two validation groups. For the discovery group, samples and data were obtained from subjects who had participated in two unrelated studies This provided an opportunity to investigate the association of influenza-related hospital admission with specific SNPs in an ethnically homogeneous, community population.
Of 2294 subjects, 500 (21.8%) had a nasopharyngeal swab that tested positive for influenza using real-time reverse transcription polymerase chain reaction (rRT-PCR) to detect the genes encoding for the matrix protein (M1) of influenza A virus and the non-structural protein 1 (NS1) of influenza B virus. Of the 500 patients with laboratory-confirmed influenza, 26 (5.2%) were hospitalized within 14 days after illness onset, 24 (4.8%) were seen at the Emergency Department within 14 days of influenza infection but were not hospitalized, and the remaining 450 (90.0%) were outpatients.
Hospitalization was used as an indicator of severe influenza infection in this study, and the discovery group sample consisted of the 26 patients hospitalized for seasonal influenza (cases) and a random sample of 993 PMRP participants (controls) (Figure 1 ).
To confirm associations observed in the discovery group, two validation groups were used ( Figure 1 
| Data collection
For cases in the discovery group, hospital discharge summaries were reviewed for all hospital admissions to confirm that acute influenza infection was a contributing factor. A review of hospital discharge summaries was not performed for cases in the two validation groups. 
| Genotyping
In the discovery group, 30 SNPs were genotyped using a multiplexed assay on the MassARRAY iPLEX SNP genotyping system (Agena Bioscience, San Diego, CA) and two SNPs (rs12252 and rs2476601)
using TaqMan assays (ThermoFisher Scientific, Grand Island, NY). The sequences of primers used for genotyping are listed in Supplemental Table S3 . Primers for the rs12252 and rs2476601 TaqMan assays were custom-designed and pre-designed, respectively. The rs12252 Taq- TaqMan assay with custom-designed primers was used to genotype rs12252 in all 84 cases and in 301 controls in the PMRP validation group. All 84 cases were also genotyped for rs8072510 using a
TaqMan assay with pre-designed primers (Supplemental Table S3 ). For the two assays, genotype concordance was 100% when replicate samples for 10% of subjects were genotyped, and the genotype call rate was 100%. In the PMRP validation group, genotype data for rs8072510 were available for 3775 controls that had been genotyped previously using the Illumina Human660 W-Quadv1_A genotyping platform. 24 In the Vanderbilt validation group, subjects had been genotyped previously for rs12252 and rs8072510 on one of four Illumina platforms: Human660W-Quadv1_A, HumanOmni1-Quad, HumanOmni5-Quad, and Human1M-Duo. 24 ,25 SNP rs8072510 was genotyped in all 128 cases and 9187 controls; SNP rs12252 was genotyped in 70 cases and 8719 controls ( Figure 1 ).
| Statistical analysis
To examine differences between hospitalized cases and other patients with influenza in the PMRP, selected characteristics of hospitalized cases in the discovery and validation groups were compared to characteristics of the 450 outpatients with laboratory-confirmed influenza in the discovery group cohort. Table S1 ) within 1 year before influenza diagnosis, and use of immunosuppressive medications within 6 months before influenza diagnosis. SNP association analyses were corrected for testing of 32 SNPs using the Bonferroni method, and a Pvalue <0.0015 (0.05/32) was considered statistically significant.
| RESULTS
Hospitalized influenza cases in the PMRP discovery and validation groups were older, had a higher prevalence of comorbid conditions and immunosuppressive medication use, and were more likely to have received an influenza vaccine during the prior 6 months compared with outpatients who had influenza ( Body mass index averaged from multiple weight and height measurements obtained during the one year period before influenza diagnosis (10 hospitalized cases in the discovery group, 5 hospitalized cases in the validation group, and 141 outpatients with influenza had missing data for body mass index). d Diagnoses of co-morbid conditions within one year before influenza diagnosis (conditions are listed in Supplemental Table S1 ).
e Medication use within the 6-month period before influenza diagnosis. f P < 0.05. g Influenza vaccination in 6-month period before influenza diagnosis. 
approximately 50% of cases in all three groups had comorbid conditions (Table 1 and Supplemental Table S4 ).
Of the 32 SNPs genotyped in the discovery group, one (interferon regulatory factor 2 (IRF2) rs59219184) was found to be monomorphic as no subject carried the minor allele. After excluding this SNP, 31 SNPs remained for analysis ( Table 2 ). All 31 SNPs were consistent with HardyWeinberg equilibrium (P > 0.01) in cases and controls in the discovery group. IFITM3 rs12252 and SFLN13 rs8072510 were also in HardyWeinberg equilibrium (P > 0.01) in the cases and controls genotyped for these SNPs in the PMRP and Vanderbilt validation groups.
In tests of allele frequency, two SNPs were associated with hospitalized influenza at the nominal P-value threshold of 0.05: schlafen family member 13 (SLFN13) rs8072510 and interferon alpha and beta receptor subunit 2 (IFNAR2) rs1131668 (Table 2 and Supplemental Table S5 ). The SLFN13 rs8072510 minor T allele had the strongest association with increased risk of hospitalized influenza in the discovery group (allelic P-value = 0.0099 for comparison with PMRP controls; Supplemental Table S5) but the P-value was not below the threshold value of 0.0015 for statistical significance based on Bonferroni adjustment. Because rs8072510 had the lowest allelic Pvalue of all the SNPs tested, associations with genotype frequency and with dominant and recessive genetic models for rs8072510 were also examined in the discovery group. Statistically significant associations were observed with genotype frequency and the recessive model (when PMRP controls were used as the comparison group in Supplemental Table S5 ), suggesting that the rs8072510 minor TT genotype was associated with hospitalized influenza. However, no association between rs8072510 and hospitalized influenza was observed in the PMRP validation group, the combined PMRP discovery and validation groups, or the Vanderbilt validation group (Supplemental Table S6 ). In addition, none of the other SNPs evaluated in this study showed associations that remained statistically significant after Bonferroni adjustment (Table 2) .
Because no associations were observed, a post-hoc analysis of the PMRP discovery group was performed to calculate the minor allele frequencies in hospitalized influenza cases that would show a statistically significant difference when compared with the observed minor allele frequencies in controls (Supplemental Table S7 ). The ratio of the calculated minor allele frequencies in cases to the observed minor allele frequencies in controls was considered as the magnitude of the fold-change in minor allele frequency that would produce a statistically significant association, assuming alpha = 0.0015 and 80% power. For the 31 SNPs, the ratio ranged from 1.9 to 60.0 with a median value of 2.8. This range indicated that a modest to large foldchange in minor allele frequency was required, depending on the SNP, for a statistically significant difference to be detected. The ratio of the observed minor allele frequencies in cases to that in controls ranged from 0.7 to 2.2 with a median value of 1.0 (Supplemental Table S7 ), suggesting that no associations were detected in Table 2 because the minor allele frequencies of most of the 31 SNPs were similar in cases and controls.
For IFITM3 rs12252, the frequency of the minor C allele was 0 in hospitalized cases in the discovery group, 0.036 in controls in the discovery group, and 0.041 in the 1000 Genomes 28 European ancestry population (Table 2 ). There was no statistically significant difference in the C allele frequency when hospitalized cases were compared with either controls (P = 0.26) or the 1000 Genomes European ancestry population (P = 0.26), using Fisher's exact test (Supplemental Table S8 ).
One hospitalized case in the PMRP validation group and four controls but no cases in the Vanderbilt validation group had the minor CC genotype (Table 3) . No statistically significant associations between rs12252 and hospitalization for seasonal influenza were observed in analyses involving the two validation groups, including when subjects at risk for influenza complications were excluded (Table 3) .
To determine whether risk factors for influenza complications modified the associations between the SNPs and hospitalized influenza, gene-environment interactions were investigated by testing for associations within risk factor categories ( Table 4) . Age is an important risk factor for influenza hospitalization; 29 therefore, associations were examined separately for cases <65 years and ≥65 years at diagnosis. Associations were also tested according to the presence or absence of other clinical risk factors for influenza complications. These exploratory analyses, performed for rs12252 (Table 4 ) and rs8072510 (Supplemental Table S9 ), did not detect differences in SNP associations with hospitalized influenza by risk factor categories, based on the P-value threshold of 0.0015.
| DISCUSSION
This pilot screening study to evaluate the association between hospitalized influenza and 32 SNPs in genes postulated to play a role in host response to seasonal influenza infection did not show statistically significant results for any of the interrogated SNPs, including IFITM3 rs12252 previously reported 3, 8, 9 to be associated with hospitalized influenza. One reason could be low power to detect associations due to the small number of hospitalized cases in the discovery group; the sample size of this group was limited by the number of individuals who both contributed DNA to the PMRP and were enrolled and tested for influenza during an acute respiratory illness. The PMRP and Vanderbilt validation groups each had a larger sample size (≥70 cases and ≥1200 controls) than the discovery group but no association between hospitalized influenza and IFITM3 rs12252 was observed in analyses of these groups. In the combined PMRP discovery and validation groups, the frequency of the rs12252 minor C allele in the 110 cases would need to be 0.131 to achieve at least 80% power to observe a difference in C allele frequency between cases and controls at alpha = 0.0015, given that the C allele frequency in the 1294 controls was 0.035. However, the C allele frequency was similar in the cases and controls. Further, the rs12252 homozygous risk genotype was found in only one hospitalized case in the PMRP validation group and was absent among hospitalized cases in the discovery group and the Vanderbilt validation group. Therefore, similar to previous reports [10] [11] [12] that observed no association between Based on GRCh38 Genome Reference Consortium Human Reference 38 (GRCh38/hg38). b Minor allele frequencies of hospitalized influenza in the discovery group compared with minor allele frequencies of controls in the discovery group and the 1000 Genomes European sample using Fisher's exact test. rs12252 and hospitalized influenza, the rs12252 minor C allele and homozygous risk genotype were present at low frequency in study populations with European ancestry.
IFITM3 restricts infection by viruses that exploit endocytosis pathways to enter host cells (such as the influenza virus) by becoming localized to endocytic vesicles and preventing fusion of the virus with endosomal cell membranes, thereby inhibiting release of virions into the host cell cytosol. 5, 7 Obstructing the endocytosis of IFITM3 protein reduces its ability to inhibit influenza virus infection. 30 The rs12252 minor C allele creates a predicted splice site that would generate a putative, truncated IFITM3 transcript lacking the first 21 N-terminal amino acids (Δ1-21 variant), 3 including the Y20 amino acid, located in a motif that is recognized and bound by the AP-2 complex leading to trafficking of IFITM3 protein to endosomes and lysosomes. 30 The Δ1-21 variant protein was shown to accumulate at the plasma membrane rather than at endosomal membranes and to have reduced activity to restrict influenza virus infection in vitro. 31, 32 Mutation or deletion of Y20 resulted in similar effects. 30, 31, 33, 34 Lymphoblastoid cells and peripheral blood mononuclear cells from individuals with the rs12252 minor CC genotype did not express the Δ1-21 variant protein; 3, 35 therefore, the relevance of the Δ1-21 variant protein to the level of severity of influenza infection in humans is unclear. At present, it is unknown whether the predicted splice site is used for splicing in vivo, and experimental studies of splice site usage are needed to determine whether the rs12252 minor C allele has a functional effect that impedes the ability of IFITM3 to restrict influenza virus infection.
A conservative approach was applied to correct for multiple testing in this study. The Bonferroni method was used when performing allele and genotype association tests for 32 SNPs to control for the probability of rejecting the null hypothesis at alpha = 0.05, given that the null hypothesis is true. Because this was a screening study, concern about generating false positive results prompted use of stringent methods to reduce the chances of false positive associations.
Hospital admission for influenza was used as a proxy for severe influenza infection in this study; however, multiple non-genetic factors increase the risk for hospital admission, including chronic disease. 36 The study accounted for some of these factors in statistical analyses, but it was not possible to adjust for all potential confounders due to the small sample size. In addition, the study was unable to account for protection from pre-existing neutralizing antibodies 37 rs5743313 in the toll-like receptor three gene) were consistent for the two subtypes (H1N1pdm09 and H7N9) examined. 40 An important limitation is that genetics may make only a small contribution to influenza severity in older adults. In the PMRP discovery and validation groups, age at influenza diagnosis was ≥65 years for>60% of cases.
Chronic disease, smoking, frailty, immunosenescence, and circulating levels of antibodies against influenza may be far more important in this age group. The analyses performed for low-risk cases in this study accounted for some of these factors, but the low-risk groups were small in size and no data were available on influenza antibody titers. If host genetics have a significant impact on risk of influenza-related hospitalization, it would most likely be observed in children who have a more limited lifetime exposure to influenza and fewer comorbid conditions. Notably, a recent study in a pediatric population observed no association between IFITM3 rs12252 and severe influenza infection, 35 similar to this study's findings for adults. Another limitation was the inability to distinguish whether hospital admission within 14 days after illness onset was a direct consequence of the primary viral infection or was due to a secondary bacterial infection. Secondary bacterial pneumonia was considered to be a complication of the primary influenza infection and to be associated with the severity of the primary infection. Therefore, regardless of whether hospital admission was because of the primary influenza infection or a secondary infection, hospitalization was considered as an indicator of severe influenza.
In conclusion, this study examined a wider selection of genetic variants for association with severe influenza in humans than previous studies, but no association was observed between the 32 SNPs in genes involved in immune defense against viral infection, including Fisher's exact test used to compare each case stratum with all 1294 controls in the combined PMRP discovery and validation groups. Genotype and allele frequencies for the controls are given in Table 3 . b Fisher's exact test used to compare each case stratum with all 8719 controls in the Vanderbilt validation group. Genotype and allele frequencies for the controls are given in Table 3 . , diagnosis of at least one co-morbid condition within 1 year before influenza diagnosis, and use of immunosuppressive medications within 6 months before influenza diagnosis.
